Patents Assigned to Syntonix Pharmaceuticals, Inc.
-
Publication number: 20140248287Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: ApplicationFiled: January 30, 2014Publication date: September 4, 2014Applicants: SYNTONIX PHARMACEUTICALS, INC., DYAX CORP.Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James Stattel, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
-
Patent number: 8815246Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: GrantFiled: September 14, 2012Date of Patent: August 26, 2014Assignees: Dyax Corp., Syntonix Pharmaceuticals, Inc.Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James Stattel, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
-
Publication number: 20130273047Abstract: The invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a hemostatic disorder comprising administering a therapeutically effective amount of a chimeric protein wherein the chimeric protein comprises at least one clotting factor and at least a portion of an immunoglobulin constant region.Type: ApplicationFiled: March 11, 2013Publication date: October 17, 2013Applicant: SYNTONIX PHARMACEUTICALS, INC.Inventor: SYNTONIX PHARMACEUTICALS, INC.
-
Publication number: 20130171138Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: ApplicationFiled: November 2, 2012Publication date: July 4, 2013Applicant: Syntonix Pharmaceuticals, Inc.Inventor: Syntonix Pharmaceuticals, Inc.
-
Patent number: 8449884Abstract: The invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a hemostatic disorder comprising administering a therapeutically effective amount of a chimeric protein wherein the chimeric protein comprises at least one clotting factor and at least a portion of an immunoglobulin constant region.Type: GrantFiled: November 18, 2010Date of Patent: May 28, 2013Assignee: Syntonix Pharmaceuticals, Inc.Inventors: Daniel S. Rivera, Robert T. Peters, Alan J. Bitonti
-
Publication number: 20130045218Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: ApplicationFiled: August 13, 2012Publication date: February 21, 2013Applicants: Syntonix Pharmaceuticals, Inc., Dyax Corp.Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James Stattel, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron Sato, Malini Viswanathan
-
Patent number: 8329182Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: November 23, 2010Date of Patent: December 11, 2012Assignee: Syntonix Pharmaceuticals, Inc.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
-
Patent number: 8293707Abstract: The invention provides novel heterodimeric fusion proteins comprising a first polypeptide including an alpha subunit of FSH (?FSH) linked directly or indirectly to a binding partner of neonatal Fc receptor (FcRn) and a second polypeptide including a beta subunit of FSH (?FSH) linked directly or indirectly to an FcRn binding partner. In one embodiment the FcRn binding partner includes an Fc fragment of an immunoglobulin, e.g., an Fc fragment of IgG. Also provided are methods making and using the fusion proteins of the invention. The invention provides a method for increasing fertility in a subject and a method for treating a subject having a disease state responsive to treatment by FSH.Type: GrantFiled: April 21, 2009Date of Patent: October 23, 2012Assignee: Syntonix Pharmaceuticals, Inc.Inventor: Susan C. Low
-
Patent number: 8273351Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: GrantFiled: April 24, 2009Date of Patent: September 25, 2012Assignees: Dyax Corp., Syntonix Pharmaceuticals, Inc.Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James Stattel, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron Sato
-
Patent number: 8101186Abstract: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.Type: GrantFiled: February 16, 2007Date of Patent: January 24, 2012Assignee: Syntonix Pharmaceuticals, Inc.Inventors: Adam R. Mezo, Kevin A. McDonnell, Cristina A. Tan Hehir, Alfredo Castro
-
Publication number: 20110230639Abstract: The invention relates to peptides derivatized with a hydrophilic polymer which, in some embodiments, bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used in some embodiments, for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates, in further embodiments, to methods of using and methods of making the peptides of the invention.Type: ApplicationFiled: August 1, 2008Publication date: September 22, 2011Applicant: Syntonix Pharmaceuticals Inc.Inventors: Adam R. Mezo, Kevin A. McDonnell
-
Patent number: 8021880Abstract: Compositions and methods for preparing Factor IX, Factor IX-containing fusion proteins, and Factor IX-containing conjugates with processing of Factor IX propeptide by PC5, are provided. In one embodiment PC5 is used to process a precursor polypeptide for a Factor IX-Fc monomer-dimer hybrid.Type: GrantFiled: July 21, 2010Date of Patent: September 20, 2011Assignee: Syntonix Pharmaceuticals, Inc.Inventors: Robert T. Peters, Alan J. Bitonti
-
Publication number: 20110182896Abstract: The invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a hemostatic disorder comprising administering a therapeutically effective amount of a chimeric protein wherein the chimeric protein comprises at least one clotting factor and at least a portion of an immunoglobulin constant region.Type: ApplicationFiled: November 18, 2010Publication date: July 28, 2011Applicant: Syntonix Pharmaceuticals, Inc.Inventors: DANIEL S. RIVERA, Robert T. Peters, Alan J. Bitonti
-
Patent number: 7862820Abstract: The invention relates to a chimeric monomer-dimer hybrid protein that comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first polypeptide chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: October 27, 2006Date of Patent: January 4, 2011Assignee: Syntonix Pharmaceuticals, Inc.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
-
Publication number: 20100310561Abstract: Natriuretic peptide fusion proteins comprising natriuretic peptides linked to antibody Fc domains, nucleic acid molecules encoding the fusion proteins disclosed herein, expression vectors expressing said fusion proteins, pharmaceutical compositions comprising said fusion proteins, and methods for their therapeutic use are disclosed.Type: ApplicationFiled: June 3, 2008Publication date: December 9, 2010Applicants: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, SYNTONIX PHARMACEUTICALS, INC.Inventors: Keith Canada, Uwe Schoenbeck, Eugene R. Hickey, Adam Mezo, Kevin McDonnell
-
Patent number: 7820162Abstract: The invention provides methods of chemically synthesizing chimeric proteins comprising at least a portion of an immunoglobulin constant region and a biologically active molecule.Type: GrantFiled: April 9, 2008Date of Patent: October 26, 2010Assignee: Syntonix Pharmaceuticals, Inc.Inventors: Adam R. Mezo, Robert T. Peters
-
Patent number: 7795400Abstract: Compositions and methods for preparing Factor IX, Factor IX-containing fusion proteins, and Factor IX-containing conjugates with processing of Factor IX propeptide by PC5, are provided. In one embodiment PC5 is used to process a precursor polypeptide for a Factor IX-Fc monomer-dimer hybrid.Type: GrantFiled: June 22, 2009Date of Patent: September 14, 2010Assignee: Syntonix Pharmaceuticals, Inc.Inventors: Robert T. Peters, Alan J. Bitonti
-
Publication number: 20090324614Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: ApplicationFiled: April 24, 2009Publication date: December 31, 2009Applicants: Dyax Corp., Syntonix Pharmaceuticals, Inc.Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James Stattel, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron Sato
-
Patent number: 7566565Abstract: Compositions and methods for preparing Factor IX, Factor IX-containing fusion proteins, and Factor IX-containing conjugates with processing of Factor IX propeptide by PC5, are provided. In one embodiment PC5 is used to process a precursor polypeptide for a Factor IX-Fc monomer-dimer hybrid.Type: GrantFiled: March 23, 2007Date of Patent: July 28, 2009Assignee: Syntonix Pharmaceuticals, Inc.Inventors: Robert T. Peters, Alan J. Bitonti
-
Patent number: 7404956Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: May 6, 2004Date of Patent: July 29, 2008Assignee: Syntonix Pharmaceuticals, Inc.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low